Treatment of female T2DM-stroke mice with CD133 + Exo significantly reduces the progression of NAFLD/NASH and improves neurological and cognitive function compared to control T2DM-stroke mice. Here, PROM1 is linked to metabolic dysfunction-associated steatohepatitis.